Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status

Withdrawn

Conditions

Transplants
Varicella

Treatments

Biological: varicella vaccine

Study type

Observational

Funder types

Other

Identifiers

NCT02692066
15-2042

Details and patient eligibility

About

Varicella zoster virus (VZV) can lead to significant morbidity and mortality in transplant recipients. Current recommendations suggest a 4 week waiting period between vaccination and transplantation and consideration of booster immunizations if antibody response does not reach target levels. This four week waiting period can result in delayed transplant, rejection of an optimal organ, or missed opportunity to vaccinate. However, these recommendations are not evidence based. This is a prospective study to look at the immune response to varicella vaccine in children with chronic liver disease. Investigators will evaluate: 1. the time at which VZV DNA becomes undetectable in blood and saliva by PCR after vaccination in children with chronic liver disease and 2. the difference in humoral and cell mediated immune response to varicella immunization between children with chronic liver disease and healthy children.

Sex

All

Ages

6 months to 21 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 6 months to 21 years
  • no history of varicella, zoster or prior varicella vaccination

Exclusion criteria

  • acute liver failure
  • liver transplant anticipated within 28 days
  • prior history of receiving blood products or immunoglobulin within 5 months prior to vaccination
  • fever
  • pregnancy
  • immunocompromised status
  • receiving immunosuppressive meds

Trial design

0 participants in 2 patient groups

Healthy Controls
Description:
Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
Treatment:
Biological: varicella vaccine
Children with Chronic Liver Disease
Description:
Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
Treatment:
Biological: varicella vaccine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems